Provider: View Press Release
Type: Link
Title: Less talk, more action: New report sponsored by ViiV Healthcare provides roadmap to achieve health equity by 2040 | GSK
Description: The report offers actions to overcome the barriers that have blocked progress in achieving health equity across HIV, STIs, & COVID-19
Provider: View Press Release
Type: Link
Title: GSK to showcase significant scientific advances in renal care at the American Society of Nephrology Kidney Week 2021 | GSK
Description: Data from all five Phase 3 trials of the ASCEND programme for the investigational medicine daprodustat will be presented at the meeting.
Provider: View Press Release
Type: Link
Title: GSK unveils plan for UK headquarters of new Consumer Healthcare company | GSK
Description: New UK-listed Consumer Healthcare company to build new global campus and innovation centre in Weybridge, UK
Provider: View Press Release
Type: Link
Title: GSK welcomes WHO recommendation for broad roll-out of its RTS,S/AS01e (RTS,S) malaria vaccine | GSK
Description: The vaccine is the result of over 30 years of research led by GSK, with PATH and other partners.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare submits FDA application for first dispersible single tablet regimen containing dolutegravir (DTG) for children living with HIV | GSK
Description: Paediatric HIV remains a global issue, with children disproportionately affected by the HIV epidemic.
Provider: View Press Release
Type: Link
Title: ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs | GSK
Description: The Phase 3 TANGO study is the 3rd trial to provide long-term evidence for Dovato reinforcing its use as a viable switch for people with HIV